Information Provided By:
Fly News Breaks for April 21, 2017
OMCL
Apr 21, 2017 | 07:17 EDT
Oppenheimer analyst Mohan Naidu raised his price target for Omnicell to $53 from $43 saying that analysis of the recent deal flow in the medication cabinets and checks with the customers point to "very healthy" competitive displacements in the quarter. Of the 19 deals the analyst identified in Q1, 16 went to Omnicell, he notes, adding that the strength in the win rate is direct result of XT platform. Naidu reiterates an Outperform rating on the shares.
News For OMCL From the Last 2 Days
There are no results for your query OMCL
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.